Oncology · Phase III

Top sponsors

• AstraZeneca 75 programs
• Chinese Academy of 70 programs
• HOFFMANN-LA ROCHE 68 programs
• MSD Merck Sharp 56 programs
• First People's Hospital 53 programs
• Ningbo Cancer Hospital 44 programs
• United Therapeutics Europe 43 programs
• Anaxis Pharma 37 programs
• AstraZeneca 37 programs
• Novartis India 32 programs
• George Institute for 29 programs
• Takeda 28 programs

1. Chemotherapy

   The First People's Hospital of Lianyungang

   Acute Lymphoblastic Leukemia

   phase 3 · small molecule · completed

   1 trial →

2. Chemotherapy

   The First People's Hospital of Lianyungang

   Endometrial Cancer

   phase 3 · small molecule · active

   1 trial →

3. Chemotherapy

   Sun Yat-sen University

   Nasopharyngeal Carcinoma

   phase 3 · small molecule · active

   1 trial →

4. Chemotherapy

   United Therapeutics Europe Ltd

   Transitional Cell Carcinoma of Ureter

   phase 3 · small molecule · active

   1 trial →

5. Chemotherapy + avelumab followed by avelumab + talazoparib

   Pfizer

   Ovarian Cancer

   phase 3 · small molecule · terminated

   1 trial →

6. Chemotherapy drug

   Chinese PLA General Hospital

   Gastric Cancer

   phase 3 · small molecule · active

   1 trial →

7. Chirhostim

   The George Institute

   Pancreatic cancer, Intraductal papillary mucinous intraductal neoplasia

   phase 3 · small molecule · active

   1 trial →

8. Cisplatin

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Nasopharyngeal Carcinoma

   phase 3 · small molecule · completed

   1 trial →

9. Cisplatin

   Children's Hospital of Fudan University

   Localized Osteosarcoma

   phase 3 · small molecule · completed

   1 trial →

10. Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Squamous Cell Carcinoma of Head and Neck

    phase 3 · small molecule · active

    1 trial →

11. Cisplatin /ml Concentrate for Advanced head and neck cancer

    Ningbo Cancer Hospital

    Advanced head and neck cancer

    phase 3 · small molecule · active

    1 trial →

12. Clifutinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Leukemia, Acute Myeloid (AML)

    phase 3 · small molecule · active

    1 trial →

13. Combination Treatment of PDS0101 and Pembrolizumab

    PDS Biotechnology Corp

    Recurrent Head and Neck Cancer

    phase 3 · other · active

    1 trial →

14. Concurrent chemotherapy

    Disc Medicine

    Uterine Cervical Neoplasms

    phase 3 · small molecule · active

    1 trial →

15. Copanlisib (Aliqopa, BAY80-6946)

    Bayer HealthCare AG

    Lymphoma,Non-Hodgkin

    phase 3 · small molecule · completed

    1 trial →

16. Cretostimogene Grenadenorepvec

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 3 · mab · active

    2 trials →

17. Custirsen

    Teva Pharma GmbH

    Prostate Cancer

    phase 3 · small molecule · completed

    1 trial →

18. Cyclophosphamide

    Children's Hospital of Fudan University

    Stage III Kidney Wilms Tumor

    phase 3 · small molecule · active

    1 trial →

19. Cyproterone acetate

    Takeda

    Adenocarcinoma, Prostate

    phase 3 · small molecule · completed

    1 trial →

20. Cytarabine

    The First People's Hospital of Lianyungang

    Leukemia

    phase 3 · small molecule · active

    1 trial →

21. Cytarabine

    Hoffmann-La Roche

    Leukemia, Myeloid, Acute

    phase 3 · small molecule · terminated

    1 trial →

22. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 · small molecule · active

    1 trial →

23. Cytokine-Induced Killer Cells

    Sun Yat-sen University

    Carcinoma, Hepatocellular

    phase 3 · mab · completed

    1 trial →

24. D-US-60010-001

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 3 · small molecule · active

    1 trial →

25. D0817C00098

    AstraZeneca AB

    BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer

    phase 3 · small molecule · active

    1 trial →

26. D081CC00006

    AstraZeneca AB

    Breast Cancer

    phase 3 · small molecule · active

    1 trial →

27. D20180177

    Pari Pharma GmbH

    Pancreatic adenocarcinoma (PAC)

    phase 3 · small molecule · active

    1 trial →

28. D3612L00005

    AstraZeneca

    HR+ / HER2- advanced breast cancer

    phase 3 · small molecule · active

    1 trial →

29. D3614C00001

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 · small molecule · active

    1 trial →

30. D3615C00001

    AstraZeneca AB

    Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer

    phase 3 · small molecule · active

    1 trial →

31. D361BC00001

    AstraZeneca AB

    Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency

    phase 3 · small molecule · active

    1 trial →

32. D361EC00001

    AstraZeneca AB

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 3 · small molecule · active

    1 trial →

33. D4191C00140

    AstraZeneca AB

    Advanced Biliary Tract Cancers

    phase 3 · small molecule · active

    1 trial →

34. D419CC00002

    AstraZeneca AB

    Advanced hepatocellular carcinoma (HCC)

    phase 3 · small molecule · active

    1 trial →

35. D419JC00001(POTOMAC)

    AstraZeneca AB

    Non-muscle invasive bladder cancer

    phase 3 · small molecule · active

    1 trial →

36. D5086C00001

    AstraZeneca AB

    MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma

    phase 3 · small molecule · active

    1 trial →

37. D5087C00001

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 · small molecule · active

    1 trial →

38. D5160C00048

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 · small molecule · active

    1 trial →

39. D5162C00042

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 · small molecule · active

    1 trial →

40. D5169C00001 FLAURA2

    AstraZeneca AB

    Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.

    phase 3 · small molecule · active

    1 trial →

41. D516FC00001(ADAURA2)

    AstraZeneca AB

    Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.

    phase 3 · small molecule · active

    1 trial →

42. D516KC00001

    AstraZeneca AB

    Non squamous non-small cell lung cancer (NSCLC)

    phase 3 · small molecule · active

    1 trial →

43. D516NC00001

    AstraZeneca AB

    Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer

    phase 3 · small molecule · active

    1 trial →

44. D533BC00001

    AstraZeneca AB

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 · small molecule · active

    1 trial →

45. D6185C00001

    AstraZeneca AB

    Patients with non-small cell lung cancer (NSCLC).

    phase 3 · small molecule · active

    1 trial →

46. D6900C00003

    AstraZeneca AB

    B7-H4-Selected Advanced/Metastatic Endometrial Cancer.

    phase 3 · small molecule · active

    1 trial →

47. D7025C00001

    AstraZeneca AB

    Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)

    phase 3 · small molecule · active

    1 trial →

48. D7029C00001

    AstraZeneca AB

    Advanced Hepatocellular Carcinoma

    phase 3 · small molecule · active

    1 trial →

Frequently asked questions